
    
      Participants na√Øve to treatment with subcutaneous (SC) interferons or oral Disease Modifying
      Therapy (DMT) who are about to start PLEGRIDY PEN therapy will be screened for participation
      in this Phase IV trial. Participants will remain on Plegridy therapy as prescribed by their
      physician. Plegridy will not be provided to participants by Biogen as a part of this study.
    
  